Obstet Gynecol Sci.  2017 Nov;60(6):506-519. 10.5468/ogs.2017.60.6.506.

What is fetal programming?: a lifetime health is under the control of in utero health

• Kwon EJ
• Kim YJ

• KMID: 2418351
• DOI: http://doi.org/10.5468/ogs.2017.60.6.506

Abstract

The "Barker hypothesis" postulates that a number of organ structures and associated functions undergo programming during embryonic and fetal life, which determines the set point of physiological and metabolic responses that carry into adulthood. Hence, any stimulus or insult at a critical period of embryonic and fetal development can result in developmental adaptations that produce permanent structural, physiological and metabolic changes, thereby predisposing an individual to cardiovascular, metabolic and endocrine disease in adult life. This article will provide evidence linking these diseases to fetal undernutrition and an overview of previous studies in this area as well as current advances in understanding the mechanism and the role of the placenta in fetal programming.

Keyword

Fetal development; Fetal nutrition disorders; Chronic disease

MeSH Terms

Adult
Chronic Disease
Critical Period (Psychology)
Embryonic and Fetal Development
Endocrine System Diseases
Fetal Development*
Fetal Nutrition Disorders
Humans
Malnutrition
Placenta

Figure

• 

  Fig. 1 Fetal adaptations to undernutrition: a framework [7]. IGF, insulin-like growth factor.

• 

  Fig. 2 The original diagrammatic representation of the thrifty phenotype hypothesis [25].

• 

  Fig. 3 An updated diagram of the thrifty phenotype hypothesis incorporating recent findings and concepts. Also included are new speculative features; maternal hyperglycemia as predisposing factor and key roles of the vascular, hypothalamic-pituitary-adrenal axis and sympathetic systems [25].

• 

  Fig. 4 Fetal programming framework, indicating the possible role of the endocrine, nutrient, and cardiovascular milieu in utero [27].

• 

  Fig. 5 Placental adaptive responses and fetal programming [55]. 11β-HSD, 11β-hydroxysteroid dehydrogenase; GLUT1, glucose transporter 1.

• 

  Fig. 6 The secernin-1 (SCRN1) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1) protein expression in the whole brain of 3-week-old offspring by using Western blot analysis [58]. C, control; FR, food-restricted. All values are given as mean±standard deviation. a) P<0.05; b) P<0.01 (Wilcoxon rank-sum test).

• 

  Fig. 7 Comparison of liver protein expression in the offspring according to maternal diet [59]. The ratio of betaine-homocysteine methyltransferase 1 (BHMT1), methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), and ATP synthase subunit beta, mitochondrial (ATP5B) density in the livers of male (A) and female (B) offspring. The number of samples (S) signify the protein density of the offspring in each group. The levels of expression of BHMT1, MTHFD1, and ATP5B were significantly reduced in the livers of the food-restricted (FR)/ad libitum (AdLib) male offspring (P<0.05, C) compared with those of the control group. The levels of BHMT1, MTHFD1, and ATP5B in the livers of female offspring did not differ among groups (D). Data are expressed as mean±standard deviation. a)P<0.05 compared with AdLib/AdLib; b),c)Significant difference of the protein expressions between sampe protein (P<0.05).

• 

  Fig. 8 A photomicrograph of male offspring livers in the 3 groups (A); the protein expression levels of mammalian target of rapamycin (mTOR) and sterol regulatory element-binding protein 1 (SREBP1) were measured by Western blotting in the 3 groups [60]. AdLib/FR, given an ad libitum diet during late gestation and an 50% food-restricted diet during lactation; cv, central vein; FR/AdLib, given a 50% food-restricted diet during late gestation and ad libitum diet during lactation. Data are present as mean±standard deviation. P-values indicate the significance of the differences among the groups (one-way analysis of variance). a)Control vs. FR/AdLib, FR/AdLib vs. AdLib/FR, control vs. AdLib/FR, P<0.05.

Reference

1. Barker DJ. In utero programming of chronic disease. Clin Sci (Lond). 1998; 95:115–128.

2. Widdowson EM, McCance RA. A review: new thoughts on growth. Pediatr Res. 1975; 9:154–156.

3. Lucas A. Programming by early nutrition in man. In : Bock GR, Whelan J, editors. The childhood environment and adult disease. Chichester: John Wiley & Sons;1991. p. 38–55.

4. Lucas A. Role of nutritional programming in determining adult morbidity. Arch Dis Child. 1994; 71:288–290.

5. Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995; 311:171–174.

6. Barker DJ. Mothers, babies, and health in later life. 2nd ed. Edinburgh: Churchill Livingstone;1998.

7. Fowden AL. Endocrine regulation of fetal growth. Reprod Fertil Dev. 1995; 7:351–363.

8. Harding JE, Johnston BM. Nutrition and fetal growth. Reprod Fertil Dev. 1995; 7:539–547.

9. Campbell AG, Dawes GS, Fishman AP, Hyman AI. Regional redistribution of blood flow in the mature fetal lamb. Circ Res. 1967; 21:229–235.

10. Rudolph AM. The fetal circulation and its response to stress. J Dev Physiol. 1984; 6:11–19.

11. Fowden AL. The role of insulin in prenatal growth. J Dev Physiol. 1989; 12:173–182.

12. Oliver MH, Harding JE, Breier BH, Evans PC, Gluckman PD. Glucose but not a mixed amino acid infusion regulates plasma insulin-like growth factor-I concentrations in fetal sheep. Pediatr Res. 1993; 34:62–65.

13. Fowden AL, Forhead AJ. Endocrine mechanisms of intrauterine programming. Reproduction. 2004; 127:515–526.

14. Osmond C, Barker DJ, Winter PD, Fall CH, Simmonds SJ. Early growth and death from cardiovascular disease in women. BMJ. 1993; 307:1519–1524.

15. Barker DJ. Maternal nutrition, fetal nutrition, and disease in later life. Nutrition. 1997; 13:807–813.

16. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993; 36:62–67.

17. Leon DA, Lithell HO, Vâgerö D, Koupilová I, Mohsen R, Berglund L, et al. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915–29. BMJ. 1998; 317:241–245.

18. Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell UB, Leon DA. Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50–60 years. BMJ. 1996; 312:406–410.

19. Barker DJ, Eriksson JG, Forsén T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002; 31:1235–1239.

20. Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens. 1996; 14:935–941.

21. Roseboom TJ, van der Meulen JH, Ravelli AC, Osmond C, Barker DJ, Bleker OP. Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview. Mol Cell Endocrinol. 2001; 185:93–98.

22. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991; 303:1019–1022.

23. Phillips DI, Hirst S, Clark PM, Hales CN, Osmond C. Fetal growth and insulin secretion in adult life. Diabetologia. 1994; 37:592–596.

24. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992; 35:595–601.

25. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001; 60:5–20.

26. Hales CN, Ozanne SE. The dangerous road of catch-up growth. J Physiol. 2003; 547:5–10.

27. Godfrey KM. The role of the placenta in fetal programming-a review. Placenta. 2002; 23:Suppl A. S20–S27.

28. Cunningham S, Cameron IT. Consequences of fetal growth restriction during childhood and adult life. Curr Obstet Gynaecol. 2003; 13:212–217.

29. Reik W, Constância M, Fowden A, Anderson N, Dean W, Ferguson-Smith A, et al. Regulation of supply and demand for maternal nutrients in mammals by imprinted genes. J Physiol. 2003; 547:35–44.

30. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf). 1997; 46:161–166.

31. Seckl JR, Cleasby M, Nyirenda MJ. Glucocorticoids, 11beta-hydroxysteroid dehydrogenase, and fetal programming. Kidney Int. 2000; 57:1412–1417.

32. Vaughan OR, Forhead AJ, Fowden AL. Glucocorticoids and placental programming. In : Burton GJ, Barker DJ, Moffett A, Thornburg KL, editors. The placenta and human developmental programming. Cambridge: Cambridge University Press;2011. p. 175–187.

33. Lesage J, Blondeau B, Grino M, Bréant B, Dupouy JP. Maternal undernutrition during late gestation induces fetal overexposure to glucocorticoids and intrauterine growth retardation, and disturbs the hypothalamo-pituitary adrenal axis in the newborn rat. Endocrinology. 2001; 142:1692–1702.

34. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet. 1993; 341:355–357.

35. Sloboda DM, Newnham JP, Moss TJ, Challis JR. The fetal hypothalamic-pituitary-adrenal axis: relevance to developmental origins of health and disease. In : Gluckman PD, Hanson MA, editors. Developmental origins of health and disease. New York (NY): Cambridge University Press;2006. p. 191–205.

36. Jellyman JK, Valenzuela OA, Fowden AL. Horse species symposium: glucocorticoid programming of hypothalamic-pituitary-adrenal axis and metabolic function: animal studies from mouse to horse. J Anim Sci. 2015; 93:3245–3260.

37. Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, et al. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology. 1996; 137:794–797.

38. Mackenzie HS, Lawler EV, Brenner BM. Congenital oligonephropathy: the fetal flaw in essential hypertension? Kidney Int Suppl. 1996; 55:S30–S34.

39. Mañalich R, Reyes L, Herrera M, Melendi C, Fundora I. Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. Kidney Int. 2000; 58:770–773.

40. Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH. Growth in utero and serum cholesterol concentrations in adult life. BMJ. 1993; 307:1524–1527.

41. Barker DJ, Meade TW, Fall CH, Lee A, Osmond C, Phipps K, et al. Relation of fetal and infant growth to plasma fibrinogen and factor VII concentrations in adult life. BMJ. 1992; 304:148–152.

42. Leeson CP, Whincup PH, Cook DG, Donald AE, Papacosta O, Lucas A, et al. Flow-mediated dilation in 9- to 11-year-old children: the influence of intrauterine and childhood factors. Circulation. 1997; 96:2233–2238.

43. Veille JC, Hanson R, Sivakoff M, Hoen H, Ben-Ami M. Fetal cardiac size in normal, intrauterine growth retarded, and diabetic pregnancies. Am J Perinatol. 1993; 10:275–279.

44. Murotsuki J, Challis JR, Han VK, Fraher LJ, Gagnon R. Chronic fetal placental embolization and hypoxemia cause hypertension and myocardial hypertrophy in fetal sheep. Am J Physiol. 1997; 272:R201–R207.

45. van Assche FA, Aerts L. The fetal endocrine pancreas. Contrib Gynecol Obstet. 1979; 5:44–57.

46. Fall CH, Stein CE, Kumaran K, Cox V, Osmond C, Barker DJ, et al. Size at birth, maternal weight, and type 2 diabetes in South India. Diabet Med. 1998; 15:220–227.

47. Fowden AL, Coan PM, Angiolini E, Burton GJ, Constancia M. Imprinted genes and the epigenetic regulation of placental phenotype. Prog Biophys Mol Biol. 2011; 106:281–288.

48. Byrne CD. Programming other hormones that affect insulin. Br Med Bull. 2001; 60:153–171.

49. Breier BH, Vickers MH, Ikenasio BA, Chan KY, Wong WP. Fetal programming of appetite and obesity. Mol Cell Endocrinol. 2001; 185:73–79.

50. Lee S, Lee KA, Choi GY, Desai M, Lee SH, Pang MG, et al. Feed restriction during pregnancy/lactation induces programmed changes in lipid, adiponectin and leptin levels with gender differences in rat offspring. J Matern Fetal Neonatal Med. 2013; 26:908–914.

51. Forhead AJ, Fowden AL. The hungry fetus? Role of leptin as a nutritional signal before birth. J Physiol. 2009; 587:1145–1152.

52. Cooper C, Javaid MK, Taylor P, Walker-Bone K, Dennison E, Arden N. The fetal origins of osteoporotic fracture. Calcif Tissue Int. 2002; 70:391–394.

53. Krebs C, Macara LM, Leiser R, Bowman AW, Greer IA, Kingdom JC. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am J Obstet Gynecol. 1996; 175:1534–1542.

54. Jansson T, Ekstrand Y, Björn C, Wennergren M, Powell TL. Alterations in the activity of placental amino acid transporters in pregnancies complicated by diabetes. Diabetes. 2002; 51:2214–2219.

55. Myatt L. Placental adaptive responses and fetal programming. J Physiol. 2006; 572:25–30.

56. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997; 277:1669–1672.

57. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19:157–167.

58. Lee JH, Yoo JY, You YA, Kwon WS, Lee SM, Pang MG, et al. Proteomic analysis of fetal programming-related obesity markers. Proteomics. 2015; 15:2669–2677.

59. You YA, Lee JH, Kwon EJ, Yoo JY, Kwon WS, Pang MG, et al. Proteomic analysis of one-carbon metabolism-related marker in liver of rat offspring. Mol Cell Proteomics. 2015; 14:2901–2909.

60. Lee S, You YA, Kwon EJ, Jung SC, Jo I, Kim YJ. Maternal food restriction during pregnancy and lactation adversely affect hepatic growth and lipid metabolism in three-week-old rat offspring. Int J Mol Sci. 2016; 17:E2115.

61. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005; 135:1382–1386.